Comparison · NCT03139604-327a9e68
Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of aGVHD Flares
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Itacitinib Plus Corticosteroids vs Placebo Plus Corticosteroids: Incidence Rate of aGVHD Flares. Trial comparisons, record NCT03139604-327a9e68. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03139604-327a9e68
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.192 | 0.145 | 0.249 | wilson | |
| Risk in group 2 | 0.218 | 0.169 | 0.277 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0264 | -0.102 | 0.0493 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.879 | 0.607 | 1.27 | log | |
| Odds ratio, group 1 over group 2 | 0.85 | 0.534 | 1.35 | log | |
| Number needed to treat, for one fewer participant with the outcome on Itacitinib Plus Corticosteroids than on Placebo Plus Corticosteroids | 37.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Itacitinib Plus Corticosteroids | Itacitinib was administered at a starting dose of 200 mg orally once daily QD (2 × 100 mg tablets) in combination with steroids i.e. methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of the disease. | 42 | 219 | OG000 |
| Group 2 | Placebo Plus Corticosteroids | Matching placebo was administered orally once daily QD in combination with steroids i.e. methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of the disease. | 48 | 220 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence Rate of aGVHD Flares
- Description
- Time frame
- up to day 100
- Population
- Full Analysis Set (FAS) Population
Source ClinicalTrials.gov
Trial
- Title
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
- NCT number
- NCT03139604
- Phases
- PHASE3
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Itacitinib, Placebo, Prednisone, Methylprednisolone
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2020-05-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03139604?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03139604-327a9e68